Xponance Inc. Reduces Position in Cencora, Inc. $COR

Xponance Inc. lowered its position in Cencora, Inc. (NYSE:COR) by 16.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 51,849 shares of the company’s stock after selling 10,323 shares during the period. Xponance Inc.’s holdings in Cencora were worth $16,204,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. United Bank raised its position in Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after purchasing an additional 305 shares during the last quarter. Brighton Jones LLC purchased a new position in shares of Cencora during the second quarter worth about $264,000. Flagship Harbor Advisors LLC increased its position in Cencora by 10.6% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 2,109 shares of the company’s stock valued at $632,000 after acquiring an additional 202 shares during the period. Hantz Financial Services Inc. lifted its position in Cencora by 712.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after acquiring an additional 178 shares during the period. Finally, Premier Path Wealth Partners LLC grew its stake in shares of Cencora by 5.6% in the 2nd quarter. Premier Path Wealth Partners LLC now owns 1,379 shares of the company’s stock valued at $413,000 after purchasing an additional 73 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Up 1.4%

Shares of NYSE COR opened at $371.86 on Friday. The stock has a market capitalization of $72.34 billion, a price-to-earnings ratio of 44.69, a price-to-earnings-growth ratio of 1.71 and a beta of 0.68. Cencora, Inc. has a 52 week low of $248.59 and a 52 week high of $377.54. The firm has a 50-day moving average price of $351.72 and a 200 day moving average price of $333.58. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period last year, the firm earned $3.73 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a $0.60 dividend. The ex-dividend date is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.6%. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

Analyst Upgrades and Downgrades

COR has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price target on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. TD Cowen raised their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wells Fargo & Company boosted their price target on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Mizuho raised their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,220 shares of company stock valued at $5,282,867 in the last 90 days. 0.38% of the stock is currently owned by insiders.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.